SCHEMBL1340547

SCHEMBL1340547

Cn1c(=O)c(-c2ccc(Cl)cc2Cl)cc2c3cc(-c4ccn[nH]4)ccc3n(COCC[Si](C)(C)C)c21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.36
▸ MAPK8 P45983 1/20 0.35
▸ L3MBTL1 Q9Y468 2/20 0.33
▸ NOTUM Q6P988 2/20 0.31
▸ BRD4 O60885 2/20 0.31
▸ BRD2 P25440 1/20 0.31
▸ BRD3 Q15059 1/20 0.31
▸ PLK1 P53350 1/20 0.31
▸ MAP2 P11137 1/20 0.31
▸ POLB P06746 1/20 0.31
▸ PTPN11 Q06124 1/20 0.31
▸ CNR1 P21554 3/20 0.31
▸ CNR2 P34972 3/20 0.31
▸ KDM4E B2RXH2 1/20 0.30
▸ ALDH1A1 P00352 1/20 0.30
▸ GAA P10253 1/20 0.30
▸ HPGD P15428 1/20 0.30
▸ HSD17B10 Q99714 1/20 0.30
▸ GABRA1 P14867 1/20 0.30
▸ GABRG2 P18507 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1339295 0.86 NPC1 (0.37) NPC1NOTUMCNR1CNR2KDM4E
SCHEMBL1339497 0.85 NPC1 (0.37) NPC1CNR1CNR2KDM4EALDH1A1
SCHEMBL1339178 0.84 NPC1 (0.36) NPC1CNR1CNR2KDM4EALDH1A1
SCHEMBL1338074 0.84 L3MBTL1 (0.40) L3MBTL1NOTUMBRD4BRD2BRD3
SCHEMBL1338115 0.82 NPC1 (0.48) NPC1CNR1CNR2ALDH1A1GABRA1
SCHEMBL1339163 0.77 NPC1 (0.43) NPC1POLBCNR1CNR2ALDH1A1
SCHEMBL1339165 0.77 NPC1 (0.43) NPC1POLBCNR1CNR2ALDH1A1
SCHEMBL1338786 0.75 L3MBTL1 (0.50) NPC1L3MBTL1NOTUMKDM4EALDH1A1
SCHEMBL1338123 0.75 L3MBTL1 (0.39) L3MBTL1NOTUMMAP2POLBPTPN11
SCHEMBL1338390 0.75 L3MBTL1 (0.43) L3MBTL1NOTUMBRD4BRD2BRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 NPC1 428/4885MAPK8 3481/4885L3MBTL1 4412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback